Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Aug 23, 2022 4:52pm
273 Views
Post# 34915391

RE:RE:RE:Financials early next week?

RE:RE:RE:Financials early next week?
Yes Eoganacht and in my post I stated " per official news release "  sure because of the nature of importance of this release it would be very welcomed to see current calendar on patients.  The upcoming Q2 release might be financial only to Q2 and patient data to current time-line if so that would be great. Either way this data will definitely give us a clear picture.  Thanks for your concern. 

Eoganacht wrote
Hi 99942Apophis - I think 30 patients should reach 270 days by the end of August. From the Nov. 29 2021 MD&A:

"As of November 29, 2021, (270 days ago) Study II has enrolled and provided the primary study treatment for 30 patients (including three patients from the Study treated at the Therapeutic Dose) for a total of 33 patients..."

Theralase planned to treat patient 25 in 3Q2021. That patient should reach 450 days some time between Friday Nov. 25 and Saturday Dec, 24. at which point Theralase plans to submit the 450 day data of the first 25 to the FDA. As of the end of August patient 25 should reach 330 days.


99942Apophis wrote: Eoganacht wrote

Last year the financials came out on Monday, Aug. 30
In 2020 they came out on Friday, August 28

So probably next Monday the 29th or Tuesday the 30th...

All eyes will be on results for those 11 pending at 270 days...



To be clear the 270 day update will be on 24 patients per official news release, patient 25 should also clear as #25 probably received  treatment  shortly after and still make the 270 day mark. 3 more trading days at best could stretch to 4  but who cares I'm cracking the champaign Friday evening. 




<< Previous
Bullboard Posts
Next >>